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Human induced pluripotent stem cells (iPSCs) are established by introducing several reprogramming
factors, such as OCT3/4, SOX2, KLF4, c-MYC. Because of their pluripotency and immortality, iPSCs are
considered to be a powerful tool for regenerative medicine. To date, iPSCs have been established all over
the world by various gene delivery methods. All methods induced high-quality iPSCs, but epigenetic
analysis of abnormalities derived from differences in the gene delivery methods has not yet been per-
formed. Here, we generated genetically matched human iPSCs from menstrual blood cells by using three
kinds of vectors, i.e., retrovirus, Sendai virus, and episomal vectors, and compared genome-wide DNA
methylation proﬁles among them. Although comparison of aberrant methylation revealed that iPSCs
generated by Sendai virus vector have lowest number of aberrant methylation sites among the three
vectors, the iPSCs generated by non-integrating methods did not show vector-speciﬁc aberrant
methylation. However, the differences between the iPSC lines were determined to be the number of
random aberrant hypermethylated regions compared with embryonic stem cells. These random aberrant
hypermethylations might be a cause of the differences in the properties of each of the iPSC lines.
© 2018, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
Human induced pluripotent stem cells (iPSCs) are powerful re-
sources for disease modeling, drug discovery, and regenerative
medicine because of their potential for pluripotency, ability to self-
renew indeﬁnitely, avoidance of rejection of their derivatives by the
immune system and for ethical issues [1]. Studies of reprogram-
ming mechanisms and characterization of iPSCs are imperative to
ensure the safety of their derivatives in regenerative medicine [2].A. Umezawa).
se Society for Regenerative
ative Medicine. Production and hoEpigenetic reprogramming is an essential event during trans-
formation from somatic cells to iPSCs. DNA methylation is an
important epigenetic modiﬁcation and has a critical role in many
aspects of normal development and disease [3e5]. Expression of
OCT3/4 and NANOG genes, known as reprogramming factors, are
induced in restricted tissues with an inverse correlation of DNA
methylation during development [6,7]. Transient ectopic expres-
sion of deﬁned reprogramming factors forces genome-wide
epigenetic exchange and transforms somatic cells to iPSCs [8e12].
After reprogramming, epigenetic proﬁles of the human iPSCs can be
clearly discriminated from the parent somatic cells and are similar
to human embryonic stem cells (ESCs), though there is a small
fraction of differentially methylated regions [11e15]. In addition,
the degree of global DNA methylation in human pluripotent stemsting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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[11,12]. This global hypermethylation of human pluripotent stem
cells is a feature shared with primed murine epiblast stem cells,
although mouse ESCs, that are naïve state stem cells, have global
hypomethylation corresponding to early embryonic cells [16e21].
Human iPSCs have been established by various gene delivery
methods. After the ﬁrst report of iPSC generation by using retro-
virus vectors [8], lentivirus vectors [22], Sendai virus vectors
[23,24], PiggyBac vectors [10], plasmid vectors [25], episomal vec-
tors [26], protein transfer [27,28], mRNA transfer [29], and miRNA
transfer [30] have been reported asmethods for iPSC generation. All
methods induced high-quality iPSCs, but epigenetic abnormalities
associated with the speciﬁc gene delivery method have not been
well analyzed. In this study, we generated human iPSCs derived
from menstrual blood cells with three kinds of vectors, i.e., retro-
virus, Sendai virus, and episomal vectors, and evaluated them for
the scale of genome-wide DNA methylation.
2. Results
2.1. Comparison of DNA methylation level in pluripotent stem cells
and somatic cells
We generated genetically matched human iPSCs from menstrual
blood cells (Edom22) in our laboratory by retrovirus vector infection
[12], episomal vector transfection or Sendai viral SeVdp-iPS vector
infection (designated as Retro-, Episomal-, and Sendai-iPSCs,
respectively) (Fig. 1A and B, Supplemental Figs. 1 and 2). To investi-
gate the differences in DNA methylation between iPSCs generated
with the threekindsofvectors,weobtainedDNAmethylationproﬁles
from ESCs, iPSCs including Retro-iPSCs, Sendai-iPSCs, and Episomal-
iPSCs, and parent somatic cells, using Illumina's Inﬁnium Human-
Methylation450K BeadChip. Methylation levels are represented as b-
values,which range from “0”, for completelyunmethylated, to “1”, for
completely methylated. Additional data sets from 5 ESCs were ob-
tained from the GEO database [31]. We completely analyzed global
DNA methylation of 49 samples (Supplemental Table 1), all with XX
karyotypes. All iPSC lines in this study were derived from the same
parental somaticcell, Edom22.Thepromoter regionsofpluripotency-
associated genes such as POU5F1, NANOG, SALL4, PTPN6, RAB25,
EPHA1, TDGF1 and LEFTY1 showed low levels ofmethylation,whereas
the promoter regions of somatic cell-associated genes such as EMI-
LIN1, LYST, RIN2 and SP100were highly methylated in all pluripotent
cells (Fig. 1C). These results indicate that all iPSC lines were
completely reprogrammed at the core genes, regardless of type of
vectorused. As assessedbyunsupervisedhierarchical clusteranalysis
(HCA) (Fig.1D)andprincipal component analysis (PCA) (Fig.1E)using
each iPSC lines (passaged about 30 times), human iPSCswere clearly
distinguishable from their parent cells and were similar to ESCs.
Sendai-iPSCs appeared to be more similar to ESCs, but no clear dif-
ference among the three methods was deﬁned.
2.2. Identiﬁcation of differentially methylated regions
In further analysis, we deﬁned a differentiallymethylated region
(DMR) between ESCs and iPSCs as a CpG site whose delta-b-value
score differed by at least 0.3 (Fig. 2A). We compared the DNA
methylation states of each iPSC line with those of ESCs (the aver-
aged value from 12 ESC lines). The number of DMRs between ESCs
and each iPSC line (ES-iPS-DMRs) ranged from 448 to 1175 in Retro-
iPSCs, from 101 to 168 in Sendai-iPSCs, and from 202 to 875 in
Episomal-iPSCs. Sendai-iPSCs had lowest number of ES-iPS-DMRs
among three kinds of vectors (Fig. 2B). The number of ES-iPS-
DMRs in all 6 Sendai-iPSCs was under 168. In Episomal-iPSCs, 2
out of 3 lines showed 300 or fewer ES-iPS-DMRs. Although 1 out of3 Retro-iPSC lines showed a relatively low number of ES-iPS-DMRs,
the range of ES-iPS-DMRs number was wider. These results suggest
that the number of ES-iPS-DMRs depended on each cell line rather
than on the vectors used for iPSC generation. ES-iPS-DMRs can be
categorized into two groups: hypermethylated and hypomethy-
lated sites in iPSCs, as compared with ESCs. There was little dif-
ference in the number of hypomethylated ES-iPS-DMRs, especially
between Sendai-iPSCs and Episomal-iPSCs (Fig. 2C). The difference
between each iPSC line therefore appears to be dependent on the
number of abnormal hypermethylated sites.
2.3. Correlation between expression of DNMT/TET genes and ES-
iPS-DMRs
In order to investigate whether abnormal hypermethylation in
iPSCs was caused by irregular expression of DNAmethyltransferases
(DNMTs) and/or Ten-eleven translocations (TETs) that induce de-
methylation, we examined expression level of DNMT and TET genes.
All iPSC lines, regardless of type of vector, showed hyper expression
of both DNMT3B and TET1 genes compared to ESC (Fig. 2D and F).
However, there was no correlation between the number of ES-iPS-
DMRs and the expression levels of DNMT3B or TET1 gene (Fig. 2E
and G). Similarly, other DNMTs (DNMT1, DNMT3A and DNMT3L) and
TETs (TET2andTET3) didnot showcorrelationbetweenthenumberof
ES-iPS-DMRs and expression level (Supplemental Fig. 3).
2.4. Vector-speciﬁc ES-iPS-DMRs
We next aimed to detect vector-speciﬁc ES-iPS-DMR. We
extracted 229 DMRs that overlapped in all 3 Retro-Edom-iPSC lines.
The 44 and 76 DMRs also overlapped in all 6 Sendai-Edom-iPSC
lines and in all 3 Episomal-Edom-iPSC lines, respectively (Fig. 3A).
Approximately 80% of ES-iPS-DMR in each vector group was
detected in only one or two lines, suggesting that most of the DMRs
occurred randomly in the genome. Comparison of each the over-
lapping ES-iPS-DMR revealed that 167, 2, 13 ES-iPS-DMRs were
detected as the Retro-, Sendai- and Episomal-iPSC-speciﬁc DMRs,
respectively. Because these aberrant methylation sites at promoter
region possibly affect gene expression, we further investigated ES-
iPS-DMRs at promoters. While no ES-iPS-DMRs overlapped for all
Sendai-iPSC lines, 44 and 5 ES-iPS-DMRs were common in all
Retro- and Episomal-iPSC lines at the promoter regions, respec-
tively (Fig. 3B). Details of vector-speciﬁc DMRs are summarized in
Table 1 and Supplemental Table 2. Interestingly, 5 ES-iPS-DMRs in
Episomal-iPSC lines appeared transiently. They were not DMRs at
different passages and in different lines (Fig. 3C). In the Retro-iPSC
line, 11 out of 44 ES-iPS-DMRs were also transient abnormal re-
gions. These results indicated that Retro-iPSCs had a small subset of
the vector-speciﬁc ES-iPS-DMRs, but iPSCs generated by non-
integrating methods did not have the vector-speciﬁc ES-iPS-
DMRs, especially those were located promoter regions.
2.5. Aberrant methylation in imprinted genes in pluripotent stem
cells
We also compared DNA methylation of imprinted genes be-
tween somatic cells and iPSCs/ESCs, and identiﬁed 413 differen-
tially methylated regions at promoter regions including 68
imprinted genes (Supplemental Table 3). These 68 genes comprised
69.4% of imprinted genes examined. Representative imprinted
genes includingMEG3,H19, PEG3, IGFR2, PEG10 and XIST in ESCs and
iPSCs showed aberrant methylation compared with parent somatic
cells, independent of the vector type (Fig. 4). In addition, most of
the aberrant methylation was not adapted during culture
(Supplemental Fig. 4).
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Edom-iPSCs (blue) and the parent somatic cell, Edom22 (purple). E, Principal component analysis (PCA) based on DNA methylation scores in the averaged ESCs (black diamond),
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Choi et al. [32] reported that hiPSCs, which were generated by
using a Sendai virus vector, were molecularly and functionally
equivalent to genetically matched hESCs. Schlaeger et al. [33] alsoreported that there were no substantial method-speciﬁc differ-
ences in DNA methylation, marker expression levels or patterns, or
developmental potential by comparing among Retro-, Lenti-, Sen-
dai-, Episomal-, and mRNA-iPSCs. Our study bridges the gap be-
tween the two previous studies. In this study, we compared iPSC
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K. Nishino et al. / Regenerative Therapy 9 (2018) 71e7874lines derived from the same parental somatic cell line, menstrual
blood-derived cells, using three types of vectors. Three types of
menstrual blood cell-derived-iPSCs are preferable for comparison
analysis to avoid any inﬂuence from different parental cells. Over
99% of CpG sites in all iPSC lines did not show differences in the
methylation levels, compared with ESCs; therefore, iPSCs were
almost identical to ESCs in epigenetics regardless of vector types
used for iPSC generation. Our ﬁndings are consistent with the re-
sults of previous studies. However, when focusing the ES-iPS-DMRs
of each iPSC line in details, we found that Sendai-iPSCs were moresimilar to ESCs than Retro- and Episomal-iPSCs at the epigenetic
scale. Also, the ranges of the numbers of ES-iPS-DMRs among
Retro-iPSC linewas wider than those seen in Sendai- and Episomal-
iPSCs. This wide variation might result from genome integration of
transgenes. Among Episomal-iPSC lines, some lines as well as
Sendai-iPSCs showed low numbers of DMRs. The differences be-
tween ESCs and iPSCs, especially Sendai- and Episomal-iPSCs,
might be derived from characteristics of each of the iPSC lines,
rather than type of vectors used for iPSC generation. The type of
vector might inﬂuence the variety of line-speciﬁc properties. The
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Table 1
Details of the vector-speciﬁc DMRs.
Type of vector Retrovirus Sendai virus Episomal Common
a) No. DMR CpG 167 2 13 39
b) Hypermethylated DMR in a) 154 0 7 5
c) Hypomethylated DMR in a) 13 2 6 34
d) % Hypermethylated DMR (b/a) 92.22% 0.00% 53.85% 12.82%
e) No. DMR CpG on Gene locus in a) 121 2 10 28
f) % Gene locus (e/a) 72.46% 100.00% 76.92% 71.79%
g) Hypermethylated DMR in e) 117 0 7 2
h) Hypomethylated DMR in e) 4 2 3 26
i) % Hypermethylated DMR (f/e) 96.69% 0.00% 70.00% 7.14%
Relationship to canonical CpG Islanda
j) CpG island in e) 94 0 6 4
k) N_Shore in e) 8 1 1 4
l) N_Shelf in e) 1 0 0 2
m) S_Shore in e) 9 0 2 3
n) S_Shelf in e) 0 1 0 0
o) non-CpG island in e) 9 0 1 15
Gene region feature categoryb
p) TSS1500 in e) 42 0 4 4
q) TSS200 in e) 24 0 2 4
r) 1stExon in e) 22 0 2 4
s) 5'UTR in e) 30 0 3 3
t) Body in e) 94 2 5 60
u) 3'UTR in e) 2 0 0 9
v) No, Gene in e) 14 2 8 41
W) No. probe in p) and q) 44 0 5 6
x) No. Gene with TSS-DMR (v and w) 12 0 5 6
a Relationship to canonical CpG Island: Shores, - 0e2 kb from CpG island; Shelves, - 2e4 kb from CpG island; N, upstream of CpG island; S, downstream of CpG island.
b Gene region feature category: Gene region feature category describing the CpG position, from UCSC. TSS200¼ 0e200 bases upstream of the transcriptional start site (TSS).
TSS1500 ¼ 200e1500 bases upstream of the TSS. 50UTR¼Within the 50 untranslated region, between the TSS and the ATG start site. Body¼ Between the ATG and stop codon;
irrespective of the presence of introns, exons, TSS, or promoters. 30UTR ¼ Between the stop codon and poly A signal. This information on HumanMethylation450K was
provided by Illumina Inc.
K. Nishino et al. / Regenerative Therapy 9 (2018) 71e78 75line-speciﬁc differences depended on the number of aberrant
hypermethylated DMRs. There was no correlation between this
aberrant hypermethylation and the expression levels of the DNMTor TET genes; therefore, this aberrant hypermethylation might be
generated at the initial reprogramming step andmaintained during
culture. Approximately 80% of aberrant hypermethylated ES-iPS-
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Fig. 4. Distribution of methylation scores at promoters of imprint genes and XIST gene. H19,MEG3, PEG3, PEG10, IGF2R and XIST genes are shown. ESCs (n ¼ 12, black circles); Retro-
Edom-iPSCs (n ¼ 3, green circles); Sendai-Edom-iPSCs (n ¼ 6, red circles); Episomal-Edom-iPSCs (n ¼ 3, blue circles); parent somatic cells, Edom22 (n ¼ 2, yellow circles). The probe
IDs and probe positions of each gene were cg17985533, TSS200 for H19, cg09926418, TSS200 forMEG3, cg13960339, TSS200 for PEG3, cg27504782, TSS1500 for PEG10, cg10894318,
TSS1500 for IGF2R and cg11717280, TSS200 for XIST. TSS200 and TSS1500 indicated the position of the probe; TSS200, 0e200 bases and TSS1500, 200e1500 bases upstream of the
transcriptional start site (TSS).
K. Nishino et al. / Regenerative Therapy 9 (2018) 71e7876DMR in each vector groupwas detected in only one or two lines and
there were no vector-speciﬁc DMRs in non-integrating methods,
suggesting that most of the DMRs occurred randomly in the
genome. Therefore, this random hypermethylation might be a
cause of the differences in the properties of each of the iPSC lines.
Aberrant methylation of some imprinted genes in ESCs and
iPSCs have been reported by several groups [12,34,35]. In this study,
we detected 68 imprinted genes that exhibited aberrant methyl-
ation, which comprised 69.4% of imprinted genes examined. These
abnormalities have been widely detected in pluripotent stem cells.Most iPSC lines as well as ESCs, were abnormally hypermethylated
at MEG3, H19, PEG3, IGFR2 and XIST, regardless of the vector type.
The aberrant methylation at imprinted gene and XIST gene pro-
moters was maintained throughout continuous passage. The
aberrant methylation of imprinted genes should therefore be
monitored for validation of PSC quality.
In conclusion, we compared genetically matched iPSCs and
revealed that there were no vector-speciﬁc aberrant methylated
regions in iPSCs generated by non-integrating methods. The line-
speciﬁc properties depended on the number of random aberrant
K. Nishino et al. / Regenerative Therapy 9 (2018) 71e78 77hypermethylated DMRs rather than type of vectors used for iPSC
generation. The differences between the vectors might inﬂuence
the variety of line-speciﬁc properties. It is noteworthy that epige-
netic information can be useful to determine iPSC quality.
4. Materials and methods
4.1. Ethics statement
Human cells were collected with ethical approval of the Insti-
tutional Review Board of National Institute for Child Health and
Development, Japan. Signed informed consent was obtained from
donors, and the specimens were irreversibly de-identiﬁed. All ex-
periments handling human cells and tissues were performed in line
with the Tenets of the Declaration of Helsinki.
4.2. Human cell culture
Menstrual blood (Edom22) cells were independently estab-
lished in our laboratory [36,37], and were maintained in the
POWEREDBY10 medium (Glyco Technica Ltd., Sapporo, Japan).
Human Retro-iPSCs were generated from Edom22 by retroviral
vector pMXs, which encodes the cDNA for human OCT3/4, SOX2, c-
MYC, and KLF4, via previously described procedures [8] with slight
modiﬁcations [11,36,38,39]. Episomal-iPSCs were established from
Edom22 by episomal vectors, pCXLE-hOCT3/4-shp53, pCXLE-hSK,
and pCXLE-hUL, via procedures described [26]. Sendai-iPSCs were
produced from Edom22 by Sendai viral vector SeVdp-iPS, which
encodes the polycistronic cDNAs for mouse Oct3/4, Sox2, c-Myc, and
Klf4, via procedures described [24]. These iPSCs clearly showed
human ESC-like characters in terms of morphology; gene expres-
sion of stem cell markers; cell-surface antigens; growth (over than
20 passages); normal karyotypes; and teratoma formation
(Supplemental Figs. 1 and 2). Non-integrating episomal vectors in
the genome or erasing SeVdp vector RNA genome was also
conﬁrmed. Human ESCs, SEES, were generated in our laboratory
[40]. Human iPSCs and ESCs weremaintained on irradiatedMEFs in
iPSellon medium (Cardio Incorporated, Osaka, Japan) supple-
mented with 10 ng/ml recombinant human basic ﬁbroblast growth
factor (bFGF, Wako Pure Chemical Industries, Ltd., Osaka, Japan).
ESC genomes [41,42] were kindly gifted from Drs. C. Cowan and T.
Tenzan (Harvard Stem Cell Institute, Harvard University, Cam-
bridge, MA).
4.3. DNA methylation analysis
DNA methylation analysis was performed using the Illumina
inﬁnium assay with the HumanMethylation450K BeadChip (Illu-
mina Inc.). Genomic DNA was extracted from the cells using
QIAamp DNA Mini Kit (Qiagen). One microgram of genomic DNA
from each sample was bisulﬁte-converted using EZ DNA Methyl-
ation kit (Zymo Research), according to the manufacturer's rec-
ommendations. Bisulﬁte-converted genomic DNA was hybridized
to the HumanMethylation450K BeadChip and the BeadChip was
scanned on a BeadArray Reader (Illumina inc.), according to the
manufacturer's instructions. Methylated and unmethylated signals
were used to compute a b-value, which was a quantitative score of
DNA methylation levels, ranging from “0”, for completely unme-
thylated, to “1”, for completely methylated. On the Human-
Methylation450K BeadChip, oligonucleotides for 485,577 CpG sites
covering more than 96% of Refseq and 95% of CpG islands were
mounted. The probe with MAF (minor allele frequency of the
overlapping variant) 5% [43] and CpG sites with0.05 “Detection
p value” (computed from the background based on negative con-
trols) were eliminated from the data for further analysis, leaving416,528 CpGs valid for use with the 49 samples tested. Average
methylation was calculated from ESCs, in which 46,681 DMRs
among each ESC line in each set were removed. In Fig. 1C, each iPSC
line (at about the 30th passage) was used and the probes were
follows; POU5F1 (cg15948871, TSS1500), NANOG (cg25540142,
TSS200), SALL4 (cg25570495, TSS200), PTPN6 (cg12690127,
TSS200), RAB25 (cg15896939, TSS200), EPHA1 (cg02376703,
TSS200), TDGF1 (cg27371741, TSS200), LEFTY1 (cg15604953,
TSS1500), EMILIN1 (cg19399165, TSS200), LYST (cg13677741,
TSS1500), RIN2 (cg17016000, TSS1500), SP100 (cg23539753,
TSS200). TSS200 and TSS1500 indicated the position of the probe;
TSS200, 0e200 bases and TSS1500, 200e1500 bases upstream of
the transcriptional start site (TSS).
4.4. Quantitative reverse transcription-PCR
Total RNA was extracted from samples by the conventional
method using ISOGEN II (NIPPON GENE, Toyama, Japan). An aliquot
of total RNA was reverse-transcribed using ReverTra Ace (TOYOBO,
Japan) with random hexamer primers. The cDNA template was
ampliﬁed using speciﬁc primers for DNMT1, DNMT3A, DNMT3B,
DNMT3L, TET1, TET2 and TET3. Expression of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as a control.
Primers used in this study are summarized in Supplemental Table 4.
Quantitative PCR was performed in at least triplicate for each
sample on LightCycler®96 Real-Time PCR system (Roche) with
Power SYBR Green PCR Master Mix (Life Technologies) using a
standard protocol. Relative expression was calculated by the ddCT
method using GAPDH as an internal standard.
4.5. Accession numbers
NCBI GEO: HumanMethylation450K BeadChip data in this study
has been submitted under accession number GSE73938 and
GSE116924. Additional data sets of 5 ESCs were obtained from
GSE31848.
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